Products for Research Use Only
RegisterLogin

PD153035 (Hydrochloride)

CAT: 0804-HY-12013-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12013-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PD153035 Hydrochloride (SU-5271 Hydrochloride) is a potent EGFR inhibitor with Ki and IC50 of 6 and 25 pM, respectively.
CAS Number
183322-45-4
Product Name Alternative
SU-5271 (Hydrochloride) ; AG1517 (Hydrochloride) ; ZM 252868 (Hydrochloride)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PD153035-Hydrochloride.html
Concentration
10mM
Purity
99.48
Solubility
DMSO : 4 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
COC1=C(C=C(C2=C1)N=CN=C2NC3=CC(Br)=CC=C3)OC.Cl
Molecular Formula
C16H15BrClN3O2
Molecular Weight
396.67
Precautions
H302, H315, H319, H335
References & Citations
[1]Bridges AJ, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4- (3-bromoanilino) -6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39 (1) :267-76.|[2]Fry DW, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265 (5175) :1093-5.|[3]Bos M, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptoractivation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3 (11) :2099-106.|[4]Kunkel MW, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 1996;13 (4) :295-302.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
EGFR/ErbB1/HER1
Citation 01
BioRxiv. 2024 Apr 4.|Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870 (3) :166981.|bioRxiv. 2025 January 18.|Cell Death Dis. 2022 Jul 25;13 (7) :647.|Elife. 2015 Feb 10:4:e05178.|Gen Comp Endocrinol. 2020 Dec 1;299:113616.|Int J Stem Cells. 2022 Nov 30;15 (4) :347-358.|J Toxicol Sci. 2023 Nov 14;48 (12) :655-663.|Nat Commun. 2018 Jun 5;9 (1) :2174.|Sci Rep. 2025 Nov 17;15 (1) :40227.

Related Products

CatalogName
HY-14346-01PD153035
HY-B0500BAlverine (hydrochloride)
HY-W714513VU0469650 (hydrochloride)
HY-W708286-01α-Pyrrolidinobutiothiophenone (hydrochloride)
HY-W492795Quifenadine (hydrochloride)
HY-W012179-01Phenylpiperazine (hydrochloride)
HY-Z6449-01Phenylephrone (hydrochloride)
HY-W209279(±) Anabasine (hydrochloride)
HY-W027446-01Pyridoxal hydrochloride
HY-W011963-01Melevodopa (hydrochloride)

Alternative Products

CatalogName
A8199-5.1PD153035 hydrochloride
E1KS1079PD153035
S1079-50mgPD153035 HCl
MBS5811608PD153035 nitrate

Popular Products